Deals19 Dec 2025, 11:37 am
Cipla Limited Inks Exclusive Supply and Marketing Agreement with Pfizer Brands
AI Summary
Cipla Limited has entered into an exclusive Supply and Marketing Agreement with Pfizer Products India Private Limited and Pfizer Limited for marketing and distribution of four Pfizer brands: Corex, Dolonex, Neksium, and Dalacin C for a period of 5 years. Pfizer will continue to manufacture, source, and supply these medicines to Cipla for India. This partnership aims to make Pfizer's medicines widely available by combining its well-established portfolio with Cipla’s deep market reach.
Key Highlights
- Cipla has entered into an exclusive Supply and Marketing Agreement with Pfizer for marketing and distribution of four Pfizer brands in India.
- The agreement is signed for a period of 5 years within the territory of India.
- Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, the proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India.
- Pfizer will continue to manufacture, source and supply these medicines to Cipla for India.
- This partnership aims to make Pfizer's medicines widely available by combining its well-established portfolio with Cipla’s deep market reach.